683 Capital Management’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.4M | Sell |
389,081
-200,919
| -34% | -$8.22M | 1.05% | 25 |
|
|
2026
Q1 | $19.6M | Buy |
590,000
+230,000
| +64% | +$6.85M | 1.02% | 25 |
|
|
2025
Q4 | $10.7M | Buy |
360,000
+35,000
| +11% | +$1.14M | 0.47% | 49 |
|
|
2025
Q3 | $11.7M | Buy |
+325,000
| New | +$10.7M | 0.61% | 41 |
|
|
2025
Q2 | – | Sell |
-295,000
| Closed | -$11.6M | – | 159 |
|
|
2025
Q1 | $11.6M | Sell |
295,000
-402,000
| -58% | -$13.5M | 0.8% | 34 |
|
|
2024
Q4 | $21M | Sell |
697,000
-438,000
| -39% | -$12.6M | 1.3% | 19 |
|
|
2024
Q3 | $26.5M | Sell |
1,135,000
-265,000
| -19% | -$5.79M | 2.02% | 11 |
|
|
2024
Q2 | $24.9M | Sell |
1,400,000
-225,000
| -14% | -$3.59M | 1.88% | 13 |
|
|
2024
Q1 | $24.7M | Sell |
1,625,000
-50,000
| -3% | -$797K | 1.81% | 15 |
|
|
2023
Q4 | $28.6M | Buy |
1,675,000
+325,000
| +24% | +$3.78M | 2.34% | 9 |
|
|
2023
Q3 | $11.3M | Buy |
+1,350,000
| New | +$18.8M | 0.88% | 38 |
|
|
2023
Q2 | – | Sell |
-775,000
| Closed | -$11.7M | – | 246 |
|
|
2023
Q1 | $11.7M | Sell |
775,000
-475,000
| -38% | -$7.22M | 0.87% | 34 |
|
|
2022
Q4 | $14.8M | Sell |
1,250,000
-1,534,000
| -55% | -$11.1M | 1.25% | 25 |
|
|
2022
Q3 | $16.5M | Sell |
2,784,000
-516,000
| -16% | -$3.38M | 1.27% | 27 |
|
|
2022
Q2 | $14M | Buy |
3,300,000
+701,105
| +27% | +$4.38M | 0.99% | 33 |
|
|
2022
Q1 | $24.7M | Buy |
2,598,895
+1,391,895
| +115% | +$16.1M | 1.32% | 18 |
|
|
2021
Q4 | $22.9M | Buy |
1,207,000
+378,729
| +46% | +$9.83M | 0.84% | 28 |
|
|
2021
Q3 | $27.6M | Buy |
828,271
+585,000
| +240% | +$18.1M | 1.08% | 25 |
|
|
2021
Q2 | $9.44M | Hold |
243,271
| – | – | 0.33% | 65 |
|
|
2021
Q1 | $11.7M | Sell |
243,271
-155,000
| -39% | -$7.45M | 0.62% | 44 |
|
|
2020
Q4 | $20.7M | Hold |
398,271
| – | – | 0.98% | 24 |
|
|
2020
Q3 | $10.7M | Hold |
398,271
| – | – | 0.78% | 32 |
|
|
2020
Q2 | $7.76M | Hold |
398,271
| – | – | 0.62% | 41 |
|
|
2020
Q1 | $3.92M | Hold |
398,271
| – | – | 0.46% | 49 |
|
|
2019
Q4 | $4.42M | Sell |
398,271
-1,729
| -0.4% | -$13.1K | 0.51% | 47 |
|
|
2019
Q3 | $2.25M | Sell |
400,000
-95,000
| -19% | -$662K | 0.25% | 60 |
|
|
2019
Q2 | $4.28M | Sell |
495,000
-30,000
| -6% | -$227K | 0.39% | 55 |
|
|
2019
Q1 | $4.22M | Buy |
525,000
+25,000
| +5% | +$135K | 0.38% | 55 |
|
|
2018
Q4 | $2.05M | Hold |
500,000
| – | – | 0.12% | 86 |
|
|
2018
Q3 | $2.8M | Buy |
+500,000
| New | +$5.71M | 0.18% | 72 |
|
Other funds holding TGTX
SCM
CAM
683 Capital Management's TGTX Position: Q2 2026 in Review
683 Capital Management reduced its TG Therapeutics (TGTX) stake by 34% in Q2 2026, selling an estimated $8.22M and leaving 389,081 shares worth $21.4M. The position accounts for 1.05% of the portfolio, ranked #25.
683 Capital Management first reported a position in TGTX in Q3 2018 and has held it in 30 quarters since. The position peaked at $28.6M in Q4 2023. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- 683 Capital Management held 389,081 shares of TG Therapeutics worth $21.4M as of Q2 2026.
- 683 Capital Management sold 200,919 TG Therapeutics shares in Q2 2026, an estimated $8.22M.
- TG Therapeutics made up 1.05% of 683 Capital Management's portfolio in Q2 2026, its #25 holding.
- 683 Capital Management first reported a position in TG Therapeutics in Q3 2018 and has held it in 30 quarters since.
- 683 Capital Management's TG Therapeutics position peaked at $28.6M in Q4 2023.
- 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.